Cargando…

An Optimized Framework for Cancer Prediction Using Immunosignature

BACKGROUND: Cancer is a complex disease which can engages the immune system of the patient. In this regard, determination of distinct immunosignatures for various cancers has received increasing interest recently. However, prediction accuracy and reproducibility of the computational methods are limi...

Descripción completa

Detalles Bibliográficos
Autores principales: Firouzabadi, Fatemeh Safaei, Vard, Alireza, Sehhati, Mohammadreza, Mohebian, Mohammadreza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116316/
https://www.ncbi.nlm.nih.gov/pubmed/30181964
http://dx.doi.org/10.4103/jmss.JMSS_2_18
_version_ 1783351578294484992
author Firouzabadi, Fatemeh Safaei
Vard, Alireza
Sehhati, Mohammadreza
Mohebian, Mohammadreza
author_facet Firouzabadi, Fatemeh Safaei
Vard, Alireza
Sehhati, Mohammadreza
Mohebian, Mohammadreza
author_sort Firouzabadi, Fatemeh Safaei
collection PubMed
description BACKGROUND: Cancer is a complex disease which can engages the immune system of the patient. In this regard, determination of distinct immunosignatures for various cancers has received increasing interest recently. However, prediction accuracy and reproducibility of the computational methods are limited. In this article, we introduce a robust method for predicting eight types of cancers including astrocytoma, breast cancer, multiple myeloma, lung cancer, oligodendroglia, ovarian cancer, advanced pancreatic cancer, and Ewing sarcoma. METHODS: In the proposed scheme, at first, the database is normalized with a dictionary of normalization methods that are combined with particle swarm optimization (PSO) for selecting the best normalization method for each feature. Then, statistical feature selection methods are used to separate discriminative features and they were further improved by PSO with appropriate weights as the inputs of the classification system. Finally, the support vector machines, decision tree, and multilayer perceptron neural network were used as classifiers. RESULTS: The performance of the hybrid predictor was assessed using the holdout method. According to this method, the minimum sensitivity, specificity, precision, and accuracy of the proposed algorithm were 92.4 ± 1.1, 99.1 ± 1.1, 90.6 ± 2.1, and 98.3 ± 1.0, respectively, among the three types of classification that are used in our algorithm. CONCLUSION: The proposed algorithm considers all the circumstances and works with each feature in its special way. Thus, the proposed algorithm can be used as a promising framework for cancer prediction with immunosignature.
format Online
Article
Text
id pubmed-6116316
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-61163162018-09-04 An Optimized Framework for Cancer Prediction Using Immunosignature Firouzabadi, Fatemeh Safaei Vard, Alireza Sehhati, Mohammadreza Mohebian, Mohammadreza J Med Signals Sens Original Article BACKGROUND: Cancer is a complex disease which can engages the immune system of the patient. In this regard, determination of distinct immunosignatures for various cancers has received increasing interest recently. However, prediction accuracy and reproducibility of the computational methods are limited. In this article, we introduce a robust method for predicting eight types of cancers including astrocytoma, breast cancer, multiple myeloma, lung cancer, oligodendroglia, ovarian cancer, advanced pancreatic cancer, and Ewing sarcoma. METHODS: In the proposed scheme, at first, the database is normalized with a dictionary of normalization methods that are combined with particle swarm optimization (PSO) for selecting the best normalization method for each feature. Then, statistical feature selection methods are used to separate discriminative features and they were further improved by PSO with appropriate weights as the inputs of the classification system. Finally, the support vector machines, decision tree, and multilayer perceptron neural network were used as classifiers. RESULTS: The performance of the hybrid predictor was assessed using the holdout method. According to this method, the minimum sensitivity, specificity, precision, and accuracy of the proposed algorithm were 92.4 ± 1.1, 99.1 ± 1.1, 90.6 ± 2.1, and 98.3 ± 1.0, respectively, among the three types of classification that are used in our algorithm. CONCLUSION: The proposed algorithm considers all the circumstances and works with each feature in its special way. Thus, the proposed algorithm can be used as a promising framework for cancer prediction with immunosignature. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC6116316/ /pubmed/30181964 http://dx.doi.org/10.4103/jmss.JMSS_2_18 Text en Copyright: © 2018 Journal of Medical Signals & Sensors http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Firouzabadi, Fatemeh Safaei
Vard, Alireza
Sehhati, Mohammadreza
Mohebian, Mohammadreza
An Optimized Framework for Cancer Prediction Using Immunosignature
title An Optimized Framework for Cancer Prediction Using Immunosignature
title_full An Optimized Framework for Cancer Prediction Using Immunosignature
title_fullStr An Optimized Framework for Cancer Prediction Using Immunosignature
title_full_unstemmed An Optimized Framework for Cancer Prediction Using Immunosignature
title_short An Optimized Framework for Cancer Prediction Using Immunosignature
title_sort optimized framework for cancer prediction using immunosignature
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116316/
https://www.ncbi.nlm.nih.gov/pubmed/30181964
http://dx.doi.org/10.4103/jmss.JMSS_2_18
work_keys_str_mv AT firouzabadifatemehsafaei anoptimizedframeworkforcancerpredictionusingimmunosignature
AT vardalireza anoptimizedframeworkforcancerpredictionusingimmunosignature
AT sehhatimohammadreza anoptimizedframeworkforcancerpredictionusingimmunosignature
AT mohebianmohammadreza anoptimizedframeworkforcancerpredictionusingimmunosignature
AT firouzabadifatemehsafaei optimizedframeworkforcancerpredictionusingimmunosignature
AT vardalireza optimizedframeworkforcancerpredictionusingimmunosignature
AT sehhatimohammadreza optimizedframeworkforcancerpredictionusingimmunosignature
AT mohebianmohammadreza optimizedframeworkforcancerpredictionusingimmunosignature